Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
Phone410-581-8042
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$501 million
Profitability
Miscellaneous
Employees420
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Medifast (NYSE:MED) Frequently Asked Questions
What is Medifast's stock symbol?
Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."
How often does Medifast pay dividends? What is the dividend yield for Medifast?
Medifast announced a quarterly dividend on Thursday, December 5th. Shareholders of record on Friday, December 27th will be paid a dividend of $1.13 per share on Thursday, February 6th. This represents a $4.52 annualized dividend and a yield of 3.91%. The ex-dividend date is Thursday, December 26th. This is an increase from Medifast's previous quarterly dividend of $0.75. View Medifast's Dividend History.
How were Medifast's earnings last quarter?
Medifast Inc (NYSE:MED) released its quarterly earnings data on Thursday, November, 7th. The specialty retailer reported $1.32 EPS for the quarter, missing the consensus estimate of $1.33 by $0.01. The specialty retailer earned $190.10 million during the quarter, compared to analyst estimates of $194.70 million. Medifast had a net margin of 10.70% and a return on equity of 62.93%. The firm's quarterly revenue was up 36.5% on a year-over-year basis. During the same period last year, the business earned $1.14 EPS. View Medifast's Earnings History.
When is Medifast's next earnings date?
What guidance has Medifast issued on next quarter's earnings?
Medifast issued an update on its FY 2019
After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $5.80-5.90 for the period, compared to the Thomson Reuters consensus estimate of $6.83. The company issued revenue guidance of $$700-710 million, compared to the consensus revenue estimate of $$750.45 million.
What price target have analysts set for MED?
4 brokerages have issued twelve-month price targets for Medifast's stock. Their forecasts range from $74.00 to $216.00. On average, they anticipate Medifast's share price to reach $140.00 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price. View Analyst Price Targets for Medifast.
What is the consensus analysts' recommendation for Medifast?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.
Has Medifast been receiving favorable news coverage?
Media stories about MED stock have trended positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medifast earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the specialty retailer a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Medifast.
Are investors shorting Medifast?
Medifast saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 4,110,000 shares, a decrease of 8.9% from the December 15th total of 4,510,000 shares. Based on an average daily trading volume, of 408,800 shares, the days-to-cover ratio is currently 10.1 days. Currently, 36.7% of the company's stock are short sold. View Medifast's Current Options Chain.
Who are some of Medifast's key competitors?
What other stocks do shareholders of Medifast own?
Who are Medifast's key executives?
Medifast's management team includes the folowing people:
- Mr. Daniel R. Chard, CEO & Director (Age 54)
- Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
- Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
- Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
- Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)
Who are Medifast's major shareholders?
Medifast's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (0.54%), Winmill & CO. Inc. (0.34%), Chickasaw Capital Management LLC (0.28%), State of Alaska Department of Revenue (0.08%), Nisa Investment Advisors LLC (0.04%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.
Which institutional investors are selling Medifast stock?
MED stock was sold by a variety of institutional investors in the last quarter, including Chickasaw Capital Management LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano and Scott Schlackman. View Insider Buying and Selling for Medifast.
Which institutional investors are buying Medifast stock?
MED stock was purchased by a variety of institutional investors in the last quarter, including Winmill & CO. Inc., Ingalls & Snyder LLC, Nisa Investment Advisors LLC and FormulaFolio Investments LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.
How do I buy shares of Medifast?
Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medifast's stock price today?
One share of MED stock can currently be purchased for approximately $115.58.
How big of a company is Medifast?
Medifast has a market capitalization of $1.34 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.
What is Medifast's official website?
How can I contact Medifast?
Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]
MarketBeat Community Rating for Medifast (NYSE MED)
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
